The University of Chicago Header Logo

Connection

Hedy Kindler to Lung Neoplasms

Back to Details
This is a "connection" page, showing publications Hedy Kindler has written about Lung Neoplasms.
Hedy Kindler
Connection Strength
4.955
Lung Neoplasms
  1. Immune Composition and Immunotherapy Outcomes of Mesothelioma With BAP1, CDKN2A, MTAP, and NF2 Alterations. J Thorac Oncol. 2025 Nov; 20(11):1615-1625.
    View in: PubMed
    Score: 0.378
  2. Treatment of Pleural Mesothelioma: ASCO Guideline Update. J Clin Oncol. 2025 Mar 10; 43(8):1006-1038.
    View in: PubMed
    Score: 0.367
  3. Reply to D. de Fonseka et al. J Clin Oncol. 2018 09 10; 36(26):2746-2747.
    View in: PubMed
    Score: 0.232
  4. Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline Summary. J Oncol Pract. 2018 04; 14(4):256-264.
    View in: PubMed
    Score: 0.228
  5. Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018 05 01; 36(13):1343-1373.
    View in: PubMed
    Score: 0.226
  6. MARS: a sense of perspective and an inconvenient truth. J Thorac Oncol. 2013 May; 8(5):e49-50.
    View in: PubMed
    Score: 0.163
  7. Peritoneal mesothelioma: the site of origin matters. Am Soc Clin Oncol Educ Book. 2013; 182-8.
    View in: PubMed
    Score: 0.159
  8. Modeling of mesothelioma growth demonstrates weaknesses of current response criteria. Lung Cancer. 2006 May; 52(2):141-8.
    View in: PubMed
    Score: 0.099
  9. Multisocietal Consensus on the Use of Cytoreductive Surgery and HIPEC for the Treatment of Diffuse Malignant Peritoneal Mesothelioma: A GRADE Approach for Evidence Evaluation and Recommendation. J Surg Oncol. 2025 Apr; 131(5):810-815.
    View in: PubMed
    Score: 0.091
  10. The International Association for the Study of Lung Cancer Mesothelioma Staging Project: Proposals for the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Pleural Mesothelioma. J Thorac Oncol. 2024 Nov; 19(11):1564-1577.
    View in: PubMed
    Score: 0.089
  11. The emerging role of pemetrexed for the treatment of malignant mesothelioma. Oncology (Williston Park). 2004 Jul; 18(8 Suppl 5):49-53.
    View in: PubMed
    Score: 0.088
  12. The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Proposal for Revision of the TNM Stage Groupings in the Forthcoming (Ninth) Edition of the TNM Classification for Pleural Mesothelioma. J Thorac Oncol. 2024 Sep; 19(9):1339-1351.
    View in: PubMed
    Score: 0.087
  13. The International Association for the Study of Lung Cancer Mesothelioma Staging Project: Proposals for the "N" Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Pleural Mesothelioma. J Thorac Oncol. 2024 Sep; 19(9):1326-1338.
    View in: PubMed
    Score: 0.087
  14. Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial. JAMA Oncol. 2024 04 01; 10(4):475-483.
    View in: PubMed
    Score: 0.087
  15. The International Association for the Study of Lung Cancer Mesothelioma Staging Project: Proposals for Revisions of the "T" Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Pleural Mesothelioma. J Thorac Oncol. 2024 Sep; 19(9):1310-1325.
    View in: PubMed
    Score: 0.087
  16. The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Expanded Database to Inform Revisions in the Ninth Edition of the TNM Classification of Pleural Mesothelioma. J Thorac Oncol. 2024 Aug; 19(8):1242-1252.
    View in: PubMed
    Score: 0.086
  17. Mesothelioma in situ of the peritoneum: report of three cases and review of the literature. Histopathology. 2024 Feb; 84(3):492-506.
    View in: PubMed
    Score: 0.085
  18. Characterizing the distribution of alterations in mesothelioma and their correlation to morphology. Am J Clin Pathol. 2023 09 01; 160(3):238-246.
    View in: PubMed
    Score: 0.083
  19. The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Updated Modeling of Prognostic Factors in Pleural Mesothelioma. J Thorac Oncol. 2023 12; 18(12):1689-1702.
    View in: PubMed
    Score: 0.083
  20. Surgical phenotype of patients with peritoneal mesothelioma and a germline mutation. Cancer. 2023 07 15; 129(14):2152-2160.
    View in: PubMed
    Score: 0.081
  21. Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations. J Thorac Oncol. 2022 07; 17(7):873-889.
    View in: PubMed
    Score: 0.076
  22. EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach. J Thorac Oncol. 2020 01; 15(1):29-49.
    View in: PubMed
    Score: 0.063
  23. Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. J Thorac Oncol. 2019 10; 14(10):1718-1731.
    View in: PubMed
    Score: 0.063
  24. Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma. Clin Cancer Res. 2019 10 01; 25(19):5787-5798.
    View in: PubMed
    Score: 0.062
  25. Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study. J Clin Oncol. 2019 04 01; 37(10):790-798.
    View in: PubMed
    Score: 0.061
  26. Correlation of patient survival with clinical tumor measurements in malignant pleural mesothelioma. Eur Radiol. 2019 Jun; 29(6):2981-2988.
    View in: PubMed
    Score: 0.060
  27. Integrative Molecular Characterization of Malignant Pleural Mesothelioma. Cancer Discov. 2018 12; 8(12):1548-1565.
    View in: PubMed
    Score: 0.059
  28. Phase II trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small-cell lung cancer. Am J Clin Oncol. 1998 Oct; 21(5):438-41.
    View in: PubMed
    Score: 0.059
  29. Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. J Thorac Oncol. 2018 11; 13(11):1655-1667.
    View in: PubMed
    Score: 0.059
  30. Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma. J Clin Oncol. 2018 10 01; 36(28):2863-2871.
    View in: PubMed
    Score: 0.059
  31. Dynamic contrast-enhanced CT for the assessment of tumour response in malignant pleural mesothelioma: a pilot study. Eur Radiol. 2019 Feb; 29(2):682-688.
    View in: PubMed
    Score: 0.058
  32. Influence of Pleurectomy and Decortication in Health-Related Quality of Life Among Patients with Malignant Pleural Mesothelioma. World J Surg. 2018 04; 42(4):1036-1045.
    View in: PubMed
    Score: 0.057
  33. Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma. Cancer Biol Ther. 2018 04 03; 19(4):316-327.
    View in: PubMed
    Score: 0.057
  34. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017 09; 18(9):1261-1273.
    View in: PubMed
    Score: 0.055
  35. Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials. Oncologist. 2017 02; 22(2):189-198.
    View in: PubMed
    Score: 0.053
  36. Amount of Epithelioid Differentiation Is a Predictor of Survival in Malignant Pleural Mesothelioma. Ann Thorac Surg. 2017 Mar; 103(3):962-966.
    View in: PubMed
    Score: 0.052
  37. The Challenge of Defining Treatment Standards for a Rare Disease: Malignant Peritoneal Mesothelioma. J Oncol Pract. 2016 10; 12(10):936-937.
    View in: PubMed
    Score: 0.052
  38. The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma. J Thorac Oncol. 2016 12; 11(12):2112-2119.
    View in: PubMed
    Score: 0.052
  39. The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma. J Thorac Oncol. 2016 12; 11(12):2089-2099.
    View in: PubMed
    Score: 0.052
  40. The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma. J Thorac Oncol. 2016 12; 11(12):2100-2111.
    View in: PubMed
    Score: 0.052
  41. PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma. Sci Rep. 2016 09 13; 6:32992.
    View in: PubMed
    Score: 0.051
  42. A Multicenter Study of Volumetric Computed Tomography for Staging Malignant Pleural Mesothelioma. Ann Thorac Surg. 2016 Oct; 102(4):1059-66.
    View in: PubMed
    Score: 0.051
  43. Unique fractal evaluation and therapeutic implications of mitochondrial morphology in malignant mesothelioma. Sci Rep. 2016 Apr 15; 6:24578.
    View in: PubMed
    Score: 0.050
  44. Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2016 Jun; 49(6):1642-7.
    View in: PubMed
    Score: 0.049
  45. Extended Pleurectomy and Decortication for Malignant Pleural Mesothelioma Is an Effective and Safe Cytoreductive Surgery in the Elderly. Ann Thorac Surg. 2015 Nov; 100(5):1868-74.
    View in: PubMed
    Score: 0.048
  46. Effects of extended pleurectomy and decortication on quality of life and pulmonary function in patients with malignant pleural mesothelioma. Ann Thorac Surg. 2015 May; 99(5):1775-80.
    View in: PubMed
    Score: 0.047
  47. Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol. 2015 Apr; 16(4):447-56.
    View in: PubMed
    Score: 0.046
  48. Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802). J Natl Cancer Inst. 2015 Jan; 107(1):336.
    View in: PubMed
    Score: 0.045
  49. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014 Dec 01; 20(23):5927-36.
    View in: PubMed
    Score: 0.045
  50. MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma. PLoS One. 2014; 9(9):e105919.
    View in: PubMed
    Score: 0.045
  51. Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma. Lung Cancer. 2014 Sep; 85(3):429-34.
    View in: PubMed
    Score: 0.044
  52. Variability of tumor area measurements for response assessment in malignant pleural mesothelioma. Med Phys. 2013 Aug; 40(8):081916.
    View in: PubMed
    Score: 0.041
  53. Disease volumes as a marker for patient response in malignant pleural mesothelioma. Ann Oncol. 2013 Apr; 24(4):999-1005.
    View in: PubMed
    Score: 0.039
  54. Three-dimensional stereoscopic volume rendering of malignant pleural mesothelioma. Int Surg. 2012 Jan-Mar; 97(1):65-70.
    View in: PubMed
    Score: 0.037
  55. Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium. Invest New Drugs. 2012 Jun; 30(3):1211-5.
    View in: PubMed
    Score: 0.036
  56. Arsenic trioxide in patients with adenocarcinoma of the pancreas refractory to gemcitabine: a phase II trial of the University of Chicago Phase II Consortium. Am J Clin Oncol. 2008 Dec; 31(6):553-6.
    View in: PubMed
    Score: 0.030
  57. The cancer and leukemia group B respiratory committee. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3581s-8s.
    View in: PubMed
    Score: 0.025
  58. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2005 Nov 01; 23(31):8033-40.
    View in: PubMed
    Score: 0.024
  59. Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma. Lung Cancer. 2024 Sep; 195:107928.
    View in: PubMed
    Score: 0.022
  60. ASO Author Reflections: Venous Thromboembolism in Peritoneal Mesothelioma. Ann Surg Oncol. 2024 Jun; 31(6):3785-3786.
    View in: PubMed
    Score: 0.022
  61. Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B. Cancer. 2003 May 15; 97(10):2480-6.
    View in: PubMed
    Score: 0.020
  62. Metastatic colorectal cancer. Curr Treat Options Oncol. 2001 Dec; 2(6):459-71.
    View in: PubMed
    Score: 0.018
  63. Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. Proc Natl Acad Sci U S A. 2019 04 30; 116(18):9008-9013.
    View in: PubMed
    Score: 0.015
  64. The clinical development of paclitaxel and the paclitaxel/carboplatin combination. Eur J Cancer. 1998 Sep; 34(10):1543-8.
    View in: PubMed
    Score: 0.015
  65. Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol. 1997 Dec; 8(12):1269-71.
    View in: PubMed
    Score: 0.014
  66. Paclitaxel and carboplatin in early phase studies: Roswell Park Cancer Institute experience in the subset of patients with lung cancer. Semin Oncol. 1997 Aug; 24(4 Suppl 12):S12-138-S12-143.
    View in: PubMed
    Score: 0.014
  67. A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). Oncologist. 2010; 15(12):1310-9.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.